1 August 1996 in American Journal of Physiology-Renal Physiology
The capacity to concentrate urine develops progressively during postnatal life in most mammalian species. Here we have examined whether low expression of the arginine vasopressin (AVP)-activated water channel aquaporin-2 (AQP-2) may be a limiting factor for the concentrating capacity in the infant rats. Urine osmolality in response to 24-h dehydration increased significantly from 10 to 40 days of age. The most rapid increase occurred during the weaning period, i.e., days 15-20. A similar developmental pattern was observed for AQP-2 mRNA levels in the renal medulla. AQP-2 protein levels also increased markedly from day 10 to 40. Immunohistochemistry revealed that AQP-2 was exclusively located in collecting duct principal cells both in infant and adult rats but that the signal was much weaker in infants. To further examine the relationship between urinary concentrating capacity and AQP-2 expression, we treated rats with a single injection of betamethasone, which is known to accelerate maturation in several organs. Twenty-four hours after treatment, there was an increase in urine osmolality, renal medullary AQP-2 mRNA, and AQP-2 protein levels in infant but not in adult rats. A single injection of a specific V2 agonist caused within 6 h significant increase of AQP-2 mRNA in both infant and adult. The expression of the mRNA of three other transporters involved in the concentrating process, medullary Na(+)-K(+)-ATPase alpha-subunit, Na-K-2Cl cotransporter, and epithelial chloride channel also increased during the weaning period and were upregulated by glucocorticoids. We conclude that there is a well-synchronized development of the many of the components that determine the concentrating capacity and that the low expression of AQP-2 is one of the limiting factors for low concentrating capacity in infants.
28 October 2021 in Journal of Biological Chemistry
The ion pump Na+,K+-ATPase is a critical determinant of neuronal excitability; however, its role in the etiology of diseases of the central nervous system (CNS) is largely unknown. We describe here the molecular phenotype of a Trp931Arg mutation of the Na+,K+-ATPase catalytic α1 subunit in an infant diagnosed with therapy-resistant lethal epilepsy. In addition to the pathological CNS phenotype, we also detected renal wasting of Mg2+. We found that membrane expression of the mutant α1 protein was low, and ion pumping activity was lost. Arginine insertion into membrane proteins can generate water-filled pores in the plasma membrane, and our molecular dynamic (MD) simulations of the principle states of Na+,K+-ATPase transport demonstrated massive water inflow into mutant α1 and destabilization of the ion-binding sites. MD simulations also indicated that a water pathway was created between the mutant arginine residue and the cytoplasm, and analysis of oocytes expressing mutant α1 detected a nonspecific cation current. Finally, neurons expressing mutant α1 were observed to be depolarized compared with neurons expressing wild-type protein, compatible with a lowered threshold for epileptic seizures. The results imply that Na+,K+-ATPase should be considered a neuronal locus minoris resistentia in diseases associated with epilepsy and with loss of plasma membrane integrity.
21 May 2002 in Acta Physiologica Scandinavica
1 July 1998 in American Journal of Physiology-Renal Physiology
Renal sympathetic nerves play a central role in the regulation of tubular Na+reabsorption. Norepinephrine (NE) and neuropeptide Y (NPY) are colocalized in renal sympathetic nerve endings. The purpose of this study is to examine the integrated effects of these neurotransmitters on the regulation of Na+-K+-ATPase, the enzyme responsible for active Na+reabsorption in renal tubular cells. Studies were performed on proximal tubular segments, which express adrenergic α- and β-receptors, as well as NPY-Y2receptors. It was found that α- and β-adrenergic agonists had opposing effects on Na+-K+-ATPase activity. β-Adrenergic agonists induced a dose-dependent inhibition of the Na+-K+-ATPase activity, whereas α-adrenergic agonists stimulated the enzyme. NPY abolished β-agonist-induced deactivation of Na+-K+-ATPase and enhanced α-agonist-induced activation of Na+-K+-ATPase. The β-adrenergic agonist appeared to inhibit Na+-K+-ATPase activity via a cAMP pathway. NPY antagonized β-agonist-induced accumulation of cAMP. In our preparation, NE alone had no net effect but stimulated the Na+-K+-ATPase activity in the presence of β-adrenergic antagonists, as well as in the presence of NPY. The results indicate that, in renal tissue, NPY determines the net effect of its colocalized transmitter, NE, by its ability to attenuate the β- and enhance the α-adrenergic effect.
1 March 2008 in The FASEB Journal
Fetal malnutrition and other factors contributing to renal growth retardation result in increased apoptosis and reduction in nephron endowment. Our group has described a novel signaling pathway, where direct interaction between Na,K‐ATPase (NKA) and IP3R triggers slow calcium oscillations and activation of NFkappaB (PNAS 2001, JBC 2003, 2006). This signaling pathway is activated by ouabain, a specific ligand of NKA. Downstream effects include protection from apoptosis and stimulation of cell proliferation (JASN 2006). Here we report activation of this signaling pathway rescues nephrogenesis in growth factor deprived (gfd) embryonic rat kidney. Kidneys from E14 rats were cultured under normal or gfd conditions and studied after 2–3 days in vitro. Exposure to ouabain triggered calcium oscillation and activated NF‐kappaB. Growth factor deprivation retarded ureter branching and formation of new glomeruli and increased apoptotic index. Exposure to nM ouabain prevented these effects. The protective effects of ouabain were abolished by depletion of intracellular calcium stores and by inhibition of NF‐kappaB, underlining the importance of the NKA‐IP3R signaling pathway. The expression of Wt1 and Pax2, which are activated by NF‐kappaB, was increased in ouabain exposed gfd kidneys. Thus we have identified a novel mechanism by which kidney development can be protected under adverse intrauterine circumstances.
1 April 2013 in The FASEB Journal
The renin angiotensin system is a principal physiological regulatory system for blood pressure and the Angiotensin type 1 receptor (AT 1 R) is an important target for treatment of hypertension. Using AT 1 R expressing HEK293a cells we study the Ca 2+ response to repeated doses of physiological, 1 nM [Ang II] and pharmacological, 100 nM [Ang II] at 0, 7 and 37 min. AT 1 R activation results in Ca 2+ release from intracellular stores. AT 1 R signaling has typically been studied at pharmacological 100 nM [Ang II]. At 100 nM [Ang II] a significant desensitization was seen in response to the 2nd dose with partial recovery observed at the 3rd dose. Mean Δ [Ca 2+ ] i was 150, 30 and 70 nM respectively. At 1 nM [Ang II] no desensitization was observed between the first two doses, both at 15 nM, and the response to the 3rd dose, 40 nM, is significantly increased. As recent studies suggest a crosstalk between AT 1 R and Voltage Gated Calcium Channels, we also studied the effect of blocking Ca 2+ channels with Nifedipine, therapeutically used in hypertension treatments, on AT 1 R response. No change to basal [Ca 2+ ] was seen in presence of Nifedipine, whilst an increase was found in Ca 2+ response from repeated doses of 1 nM [Ang II], 130, 110 and 80 nM. The same trend was seen in Podocyte enriched primary cultures. In summary this study shows novel aspects to the AT 1 R signaling modulation with implications for the treatment of hypertension.